When was Levicept founded?

Levicept was founded in 2012 and raised its 1st funding round within a year of its incorporation.

Where is Levicept located?

Levicept is headquartered in Sandwich, United Kingdom.

How many employees does Levicept have?

As of Jul 31, 2026, the latest employee count at Levicept is 11.

Is Levicept a funded company?

Levicept is a funded company, having raised a total of $50.9M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 2012.

How much is Levicept worth?

The latest valuation of Levicept is $***** as of Nov 17, 2020.

When was the latest funding round of Levicept?

Levicept's latest funding was a $***** Series B round on Sep 2021, with participation from 4 investors. Its primary sector is Orthopedics. In United Kingdom, the Orthopedics sector has seen $48.1M in funding in 2026 to date.

Where does Levicept rank among its competitors?

Levicept ranks 289th amongst 2848 active competitors, of which 932 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Levicept?

Levicept's top competitors include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Levicept - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for the treatment of chronic pain. The biological therapy LEVI-04 p75NTR-Fc for the treatment of chronic pain delivers neurotrophin homeostasis by providing stable binding proteins for the excess neurotrophins present in chronic pain.

Website: levicept.com
Social
Email ID: *****@levicept.com

Key Metrics

Founded Year

2012

Location

Sandwich, United Kingdom

Stage

Series B

Total Funding

$50.9M in 8 rounds

Latest Funding Round

Series B, Sep 2021, $*****

Post Money Valuation

$***** as on Nov 17, 2020

Investors

Gilde Healthcare & 9 more

Ranked

289^th among 2848 active competitors

Employee Count

11 as on Jul 31, 2026

Similar Companies

Heron Therapeutics & 406 more

View Levicept's full profile

Levicept is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Levicept Limited CIN: 8190142 , Germany, Active	Aug 22, 2012	-	9 (As on Sep 30, 2023)
Levicept Ltd CIN: 8190142 , United Kingdom, Active	Aug 22, 2012	-	7 (As on Sep 30, 2022)

Levicept has raised a total funding of $50.9M over 8 rounds. Its first funding round was on Mar 2012. Its latest funding round was a Series B round on Sep 2021 for $*****. 4 investors participated in its latest round. Levicept has 9 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Levicept:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 2021	9936827	Series B	4806169	1544402	7377353	4960956
Nov 17, 2020	6916334	Series B	9446116	1970925	8855322	5419442
Sep 14, 2016	4781705	Series A	4318800	1496178	4877803	1225768

Access funding benchmarks and valuations. Sign up today!

View details of Levicept's funding rounds and investors

Here are the details of Levicept's key team members:

Eliot Forster: CEO of Levicept.

Levicept's Board of Directors

Levicept's board has 7 active members. Kevin Stuart Johnson, Eliot Richard Forster and Simon Westbrook are part of team and Francesco Rubertis, Md Paul Peter Tak, Arthur Franken and Rajesh Bhikhu Parekh are independent board members.

Here is the list of Levicept's board of directors:

Name	Type	Representing	Status	Duration
Simon Westbrook	Team	-	Current	14y 0m
ruavcwx	Team	-	Current	5y 4m
Kevin Stuart Johnson	Investor	-	Current	14y 0m
Francesco Rubertis	Independent board member	-	Current	5y 9m
rpimbyg	Independent board member	-	Current	9y 8m
yuubisj	Independent board member	-	Current	7y 2m
vbbcrex	Independent board member	-	Current	3y 9m
ltsdhcd	Independent board member	-	Past	4y 2m
oimoqky	Independent board member	-	Past	3y 6m

View details of Levicept's Founder profiles and Board Members

Levicept's employee count trend

Levicept has 11 employees as of Jul 26. Here is Levicept's employee count trend over the years:

Uncover Levicept's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Levicept include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Here is the list of Top 10 competitors of Levicept, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
289th	Levicept 2012, Sandwich (United Kingdom), Series B	Developer of therapeutics for the treatment of chronic pain	$50.9M	Gilde Healthcare, Advent Life Sciences & 8 others	55/100